Omeros (Omeros) Beneish M-Score : 0.00 (As of May. 14, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Omeros Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Omeros's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Omeros was 18.81. The lowest was -8.51. And the median was -2.56.

Omeros Beneish M-Score Historical Data

The historical data trend for Omeros's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Beneish M-Score Chart

Omeros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Get a 7-Day Free Trial

Omeros Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beneish M-Score	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Omeros's Beneish M-Score

For the Biotechnology subindustry, Omeros's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omeros's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Omeros's Beneish M-Score falls into.

Omeros Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Omeros for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Dec23) TTM:

Last Year (Dec22) TTM:

Total Receivables was $37.47 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $217.90 Mil.
Total Assets was $378.27 Mil.
Property, Plant and Equipment(Net PPE) was $20.58 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.92 Mil.
Selling, General, & Admin. Expense(SGA) was $49.66 Mil.
Total Current Liabilities was $53.32 Mil.
Long-Term Debt & Capital Lease Obligation was $231.30 Mil.
Net Income was -9.068 + -37.75 + -37.294 + -33.701 = $-117.81 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -34.825 + -32.647 + -32.341 + 174.539 = $74.73 Mil.

Total Receivables was $242.02 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $443.24 Mil.
Total Assets was $590.97 Mil.
Property, Plant and Equipment(Net PPE) was $23.25 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.95 Mil.
Selling, General, & Admin. Expense(SGA) was $50.67 Mil.
Total Current Liabilities was $136.38 Mil.
Long-Term Debt & Capital Lease Obligation was $243.33 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(37.469 / 0)	/	(242.018 / 0)
	=		/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (217.898 + 20.581) / 378.269)	/	(1 - (443.236 + 23.254) / 590.969)
	=	0.369552	/	0.210635
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.952 / (0.952 + 23.254))	/	(0.92 / (0.92 + 20.581))
	=	0.039329	/	0.042789
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(49.66 / 0)	/	(50.668 / 0)
	=		/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((231.298 + 53.316) / 378.269)	/	((243.332 + 136.383) / 590.969)
	=	0.752412	/	0.642529
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-117.813 - 0	-	74.726)	/	378.269
	=	-0.509

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Omeros Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Omeros's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros (Omeros) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (NAS:OMER) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Executives

Demopulos Gregory A Md	director, 10 percent owner, officer: Chairman, CEO & President	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Demopulos Peter A Md	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Arnold C Hanish	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas J. Cable	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Diana T. Perkinson	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Michael A Jacobsen	officer: VP Finance and CAO	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Kurt Zumwalt	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Peter B Cancelmo	officer: See Remarks	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas F. Bumol	director	201 ELLIOT AVENUE WEST, SEATTLE WA 98119
Marcia S. Kelbon	officer: VP Patent and General Counsel	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Ray Aspiri	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Hood Leroy E. Md Phd	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Rajiv Shah	director	C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Jean-philippe Tripet	director	1420 FIFTH AVENUE, SUITE 2600, SEATTLE WA 98101-2347